Dr. Dirk Grimm

CellNetworks / BioQuant
Department of Infectious Diseases, Virology Heidelberg University
69120 Heidelberg, Germany

Phone: +49 6221-54 51339
Fax:      +49 6221-54 51481
Email:   dirk.grimm@bioquant.uni-heidelberg.de


Adeno-associated viral (AAV) gene transfer vectors, pathogen interactions with human host cells, RNA interference (RNAi) mechanisms and role in viral and parasital disease, in vitro and in vivo RNAi screens for gene and miRNA annotation, development of new AAV/RNAi-based clinical modalities to treat and prevent human infections, characterization of circulating miRNAs as novel biomarkers for infection, use of AAV/RNAi technologies to create and modify human induced pluripotent stem cells


Chica and Heinz Schaller Foundation research group leader grant, Cluster of Excellence CellNetworks, Baden-Württemberg-Stiftung (2010-2014), BMBF (2011-2014), Helmholtz Initiative on Synthetic Biology (2013-2014), Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg (2013-2014), Collaboration grant from Heidelberg University Hospital & Orthopedic Hospital (2011-2013), Industry support (2010-2013); Currently supervising 5 doctoral theses.


2007 3rd place amongst ‘Top 13 Medicine Stories 2006’ in Discover magazine
2007/6/4 Travel grants from American Society of Gene Therapy (ASGT)
2006 Plenary talk at Presidential Symposium of 2006 ASGT meeting
1998 Summa cum laude (PhD ‘with highest honor’)
1995-1998 PhD student grant from Progen Biotechnik GmbH, Heidelberg

2007–present Group leader “Virus-Host Interactions”, Heidelberg University, Germany
2006–2007 Research Associate, Stanford University, School of Medicine, CA, USA
2001–2006 Postdoctoral Fellow, Stanford University, School of Medicine, CA, USA
1999–2001 Postdoctoral Fellow, German Cancer Research Center, Heidelberg, Germany
1998 PhD (Biology) with summa cum laude, Heidelberg University, Germany
1994 Diploma (Biology), University of Kaiserslautern, Germany
1988–1994  Study of Biology (Universities of Kaiserslautern and Heidelberg, Germany)

Börner K, Niopek D, Cotugno G, Kaldenbach M, Pankert T, Willemsen J, Zhang X, Schürmann N, Mockenhaupt S, Serva A, Hiet AS, Wiedtke E, Castoldi M, Starkuviene V, Erfle H, Gilbert DF, Bartenschlager R, Boutros M, Binder M, Streetz K, Kräusslich HG and Grimm D, Robust RNAi enhancement via human Argonaute-2 over-expression from plasmids, viral vectors and cell lines. Nucleic Acids Res. 2013; in press

Schürmann N, Trabuco LG, Bender C, Russell RB and Grimm D, Molecular dissection of human Argonaute proteins by DNA shuffling. Nat. Struct. & Mol. Biol. 2013; 20: 818-826

Beer S, Bellovin DI, Lee JS, Komatsubara K, Wang LS, Koh S, Börner K, Storm TA, Davis CR, Kay MA, Felsher DW and Grimm D, Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in mice. Mol. Ther. 2010; 18: 161-170

Grimm D, Wang L, Lee JS, Schürmann N, Gu S, Börner K, Storm TA and Kay MA, Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J. Clin. Invest. 2010; 120: 3106-3119

Grimm D, Streetz KS, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F and Kay MA, Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441: 537-541

Click here for further publications.